Literature DB >> 8681977

Plasma endotoxin and cytokine levels in neutropenic and non-neutropenic bacteremic patients.

M Hynninen1, M Valtonen, M Vaara, H Markkanen, P Kuusela, H Saxen, O Takkunen.   

Abstract

Plasma endotoxin, tumor necrosis factor-alpha (TNF-alpha), interleukin 1 beta (IL-1 beta), interleukin 1 receptor antagonist (IL-1ra), and interleukin 6 (IL-6) concentrations in 69 bacteremic patients were compared with those in 54 nonbacteremic patients suffering from suspected bacterial infections. Only three (11%) of the 27 patients with gram-negative bacteremia showed detectable levels of endotoxin. TNF-alpha was detected in 6% of the bacteremic patients and in none of the nonbacteremic patients. Median IL-6 levels were significantly higher in bacteremic than in nonbacteremic patients (55 vs. 0 pg/ml, p = 0.0008). IL-6 concentrations were similar in neutropenic and non-neutropenic bacteremic patients (median 55 vs. 74 pg/ml). In contrast, neutropenic bacteremic patients had significantly lower concentrations of IL-1ra than non-neutropenic bacteremic patients (250 vs. 1,950 pg/ml, p < 0.0001). Patients with fatal bacteremia had significantly higher concentrations of IL-6 and IL-1ra than the survivors (median, 450 vs. 40, p = 0.012 and 7,600 vs. 420 pg/ml, p = 0.0075, respectively). Determinations of endotoxin or TNF-alpha in patients with suspected bacteremia failed to offer clinically relevant data on the prognosis of these patients. IL-6 levels correlated with both the presence of bacteremia and the risk of death. Granulocytopenic patients with bacteremia had lower levels of circulating IL-1ra than patients with normal granulocyte counts, and these levels correlated with poor outcome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8681977     DOI: 10.1007/bf01590936

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  27 in total

1.  Interleukin-1 receptor antagonist reduces mortality from endotoxin shock.

Authors:  K Ohlsson; P Björk; M Bergenfeldt; R Hageman; R C Thompson
Journal:  Nature       Date:  1990-12-06       Impact factor: 49.962

2.  C-reactive protein: a valuable aid for the management of febrile children with cancer and neutropenia.

Authors:  M E Santolaya; J Cofre; V Beresi
Journal:  Clin Infect Dis       Date:  1994-04       Impact factor: 9.079

Review 3.  Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts.

Authors:  E Roilides; P A Pizzo
Journal:  Clin Infect Dis       Date:  1992-09       Impact factor: 9.079

4.  Endotoxemia in human septic shock.

Authors:  R L Danner; R J Elin; J M Hosseini; R A Wesley; J M Reilly; J E Parillo
Journal:  Chest       Date:  1991-01       Impact factor: 9.410

5.  High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group.

Authors:  T Calandra; J Gerain; D Heumann; J D Baumgartner; M P Glauser
Journal:  Am J Med       Date:  1991-07       Impact factor: 4.965

6.  Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease.

Authors:  P Brandtzaeg; P Kierulf; P Gaustad; A Skulberg; J N Bruun; S Halvorsen; E Sørensen
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

7.  Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome.

Authors:  L C Casey; R A Balk; R C Bone
Journal:  Ann Intern Med       Date:  1993-10-15       Impact factor: 25.391

8.  Detection of circulating tumor necrosis factor after endotoxin administration.

Authors:  H R Michie; K R Manogue; D R Spriggs; A Revhaug; S O'Dwyer; C A Dinarello; A Cerami; S M Wolff; D W Wilmore
Journal:  N Engl J Med       Date:  1988-06-09       Impact factor: 91.245

9.  Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans.

Authors:  P Damas; A Reuter; P Gysen; J Demonty; M Lamy; P Franchimont
Journal:  Crit Care Med       Date:  1989-10       Impact factor: 7.598

10.  Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans.

Authors:  D B Kuhns; W G Alvord; J I Gallin
Journal:  J Infect Dis       Date:  1995-01       Impact factor: 5.226

View more
  6 in total

1.  Endotoxemia as a diagnostic tool for patients with suspected bacteremia caused by gram-negative organisms: a meta-analysis of 4 decades of studies.

Authors:  James C Hurley; Piotr Nowak; Lars Öhrmalm; Charalambos Gogos; Apostolos Armaganidis; Evangelos J Giamarellos-Bourboulis
Journal:  J Clin Microbiol       Date:  2015-01-28       Impact factor: 5.948

2.  An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients.

Authors:  A Engel; E Mack; P Kern; W V Kern
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

3.  Does gram-negative bacteraemia occur without endotoxaemia? A meta-analysis using hierarchical summary ROC curves.

Authors:  J C Hurley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-29       Impact factor: 3.267

4.  Diagnosis of endotoxemia with gram-negative bacteremia is bacterial species dependent: a meta-analysis of clinical studies.

Authors:  James C Hurley
Journal:  J Clin Microbiol       Date:  2009-09-30       Impact factor: 5.948

Review 5.  Endotoxemia and mortality prediction in ICU and other settings: underlying risk and co-detection of gram negative bacteremia are confounders.

Authors:  James C Hurley; Bertrand Guidet; Georges Offenstadt; Eric Maury
Journal:  Crit Care       Date:  2012-08-07       Impact factor: 9.097

6.  Plasma interleukin-8, interleukin-10, and E-selectin levels in neutropenic and non-neutropenic bacteremic patients.

Authors:  M Hynninen; M Valtonen; M Vaara; H Markkanen; P Kuusela; H Saxen; O Takkunen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-08       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.